Brief: Assembly Biosciences Reports Positive Interim Phase 1A Results From Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
23/09/2024 14:26
Sept 23 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES REPORTS POSITIVE INTERIM PHASE 1A
RESULTS
FROM CLINICAL TRIAL EVALUATING LONG-ACTING HELICASE-PRIMASE
INHIBITOR CANDIDATE ABI-5366
* ASSEMBLY BIOSCIENCES INC - ABI-5366 WELL-TOLERATED WITH
FAVORABLE SAFETY PROFILE UP TO 70 DAYS
Source text for Eikon: ID:nGNX7HTTBJ
Further company coverage: ASMB.O
((Reuters.Briefs@thomsonreuters.com;))